{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:09:14Z","timestamp":1789711754926,"version":"4.0.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are established procedures for end-stage joint disease, but perioperative blood loss remains a practical concern. Oxidized regenerated cellulose (ORC) has been used as a local hemostatic material during arthroplasty; however, its comparative value in contemporary blood-management protocols remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, and Scopus were searched from inception to March 2026. Randomized controlled trials and comparative observational studies were eligible if they evaluated ORC in THA or TKA and reported blood-loss-related or complication-related outcomes. Continuous outcomes were pooled as mean differences (MDs), and dichotomous outcomes as risk ratios (RRs), with 95% confidence intervals (CIs). Random-effects models were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies were included. Compared with no ORC or standard care, ORC was associated with lower total perioperative blood loss (MD\u2009=\u2009\u2212124.77\u2005mL, 95% CI \u2212181.71 to \u221267.83;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001), postoperative or hidden blood loss (MD\u2009=\u2009\u2212136.54\u2005mL, 95% CI \u2212214.97 to \u221258.10;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0006), and hemoglobin drop\/loss (MD\u2009=\u2009\u22120.57\u2005g\/dL, 95% CI \u22120.81 to \u22120.34;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.00001). No significant differences were found for intraoperative blood loss, transfusion rate, thrombotic events, or overall complications. Compared with active topical comparators, ORC showed no clear advantage. Evidence for ORC plus TXA vs. TXA alone was based on a single study and should be interpreted as exploratory. These effects mainly represent surrogate outcomes rather than definitive patient-important benefits.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ORC may modestly reduce blood-loss-related surrogate outcomes when compared with no ORC or standard care. Current evidence does not show clear superiority over active topical comparators or establish definite incremental benefit in TXA-based protocols. Because overall certainty remains limited, routine ORC use in unselected arthroplasty patients is not supported; future trials should focus on patient-important outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO registration number: CRD420261384870.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2026.1900156","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:12Z","timestamp":1789709772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical oxidized regenerated cellulose for perioperative blood management in total hip and knee arthroplasty: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Wenbo","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Joint Surgery, Tianjin Hospital of Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Tianjin Hospital of Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Tianjin Hospital of Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Tianjin Hospital of Tianjin University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(07)60457-7","article-title":"The operation of the century: total hip replacement","volume":"370","author":"Learmonth","year":"2007","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(18)32344-4","article-title":"Knee replacement","volume":"392","author":"Price","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2106\/JBJS.F.00222","article-title":"Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030","volume":"89","author":"Kurtz","year":"2007","journal-title":"J Bone Joint Surg Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1302\/0301-620X.86B4.14508","article-title":"Hidden blood loss following hip and knee arthroplasty: correct management of blood loss should take hidden loss into account","volume":"86","author":"Sehat","year":"2004","journal-title":"J Bone Joint Surg Br"},{"key":"B5","doi-asserted-by":"publisher","first-page":"g4829","DOI":"10.1136\/bmj.g4829","article-title":"Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety","volume":"349","author":"Poeran","year":"2014","journal-title":"Br Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1016\/j.arth.2018.08.002","article-title":"Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society","volume":"33","author":"Fillingham","year":"2018","journal-title":"J Arthroplasty"},{"key":"B7","doi-asserted-by":"publisher","first-page":"115585","DOI":"10.1016\/j.carbpol.2019.115585","article-title":"Oxidized cellulose-based hemostatic materials","volume":"230","author":"Zhang","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10047-005-0296-x","article-title":"Clinical benefits and risk analysis of topical hemostats: a review","volume":"8","author":"Tomizawa","year":"2005","journal-title":"J Artif Organs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/08941939.2018.1458166","article-title":"Oxidized regenerated cellulose can reduce hidden blood loss after total hip arthroplasty: a retrospective study","volume":"32","author":"Wang","year":"2019","journal-title":"J Invest Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12891-023-06932-7","article-title":"Hemostatic effect and safety evaluation of oxidized regenerated cellulose in total knee arthroplasty-a randomized controlled trial","volume":"24","author":"Li","year":"2023","journal-title":"BMC Musculoskelet Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1515610","DOI":"10.3389\/fsurg.2024.1515610","article-title":"Hemostatic effect of oxidized regenerated cellulose vs. Topical tranexamic acid in total knee arthroplasty-a prospective randomized controlled trial","volume":"11","author":"Li","year":"2025","journal-title":"Front Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10760296241306749","DOI":"10.1177\/10760296241306749","article-title":"Safety and efficacy of a novel hemostatic powder in total knee arthroplasty","volume":"30","author":"Wang","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"B13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13018-025-05782-4","article-title":"The efficacy of oxidised regenerated cellulose powder in reducing blood loss during primary total hip arthroplasty: a retrospective cohort study","volume":"20","author":"Yoon","year":"2025","journal-title":"J Orthop Surg Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s13018-025-05913-x","article-title":"Oxidized regenerated cellulose powder reduces perioperative bleeding and thigh swelling in total hip arthroplasty: a prospective interventional study","volume":"20","author":"Ishikura","year":"2025","journal-title":"J Orthop Surg Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1007\/s00402-024-05475-3","article-title":"Perioperative bleeding control in total hip arthroplasty: hemostatic powder vs. Tranexamic acid-a prospective randomized controlled trial","volume":"144","author":"Wakasa","year":"2024","journal-title":"Arch Orthop Trauma Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1051\/sicotj\/2025036","article-title":"Clinical efficacy of oxidized regenerated cellulose powder in perioperative blood management in direct anterior total hip arthroplasty","volume":"11","author":"Kaneko","year":"2025","journal-title":"SICOT J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e94414","DOI":"10.7759\/cureus.94414","article-title":"Hemostatic effect of oxidized regenerated cellulose in simultaneous bilateral total knee arthroplasty: a retrospective study","volume":"17","author":"Sato","year":"2025","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.arth.2025.08.019","article-title":"The effect of intraoperative administration of oxidized regenerated cellulose on blood loss and thigh swelling after total knee arthroplasty: a single-blind randomized controlled trial","volume":"41","author":"Ueyama","year":"2026","journal-title":"J Arthroplasty"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100921","DOI":"10.1016\/j.jorep.2026.100921","article-title":"Comparison of topical hemostatic effects between oxidized regenerated cellulose and gelatin-thrombin-based hemostatic matrix in total knee arthroplasty","author":"Hanada","year":"2026","journal-title":"J Orthop Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B22","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2021"},{"key":"B23","year":"2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/ALN.0b013e318254d1a3","article-title":"Patient blood management","volume":"116","author":"Goodnough","year":"2012","journal-title":"Anesthesiology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jama.2019.0554","article-title":"Patient blood management: recommendations from the 2018 Frankfurt consensus conference","volume":"321","author":"Mueller","year":"2019","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10760296261420230","DOI":"10.1177\/10760296261420230","article-title":"Effectiveness and safety of oxidized regenerated cellulose for hemostasis in joint arthroplasty: a systematic review and meta-analysis","volume":"32","author":"Xiao","year":"2026","journal-title":"Clin Appl Thromb Hemost"},{"key":"B27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/SLA.0b013e3181c3bcca","article-title":"A comprehensive review of topical hemostatic agents: efficacy and recommendations for use","volume":"251","author":"Achneck","year":"2010","journal-title":"Ann Surg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"znad361","DOI":"10.1093\/bjs\/znad361","article-title":"Topical haemostatic agents in surgery","volume":"111","author":"Brown","year":"2024","journal-title":"BJS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10760296231190376","DOI":"10.1177\/10760296231190376","article-title":"Safety and hemostatic effectiveness of SURGICEL powder in mild and moderate intraoperative bleeding","volume":"29","author":"Al-Attar","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e3054","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis","volume":"344","author":"Ker","year":"2012","journal-title":"Br Med J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"CD001886","DOI":"10.1002\/14651858.CD001886.pub4","article-title":"Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion","volume":"2011","author":"Henry","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1900156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:13Z","timestamp":1789709773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1900156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":33,"alternative-id":["10.3389\/fsurg.2026.1900156"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1900156","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1900156"}}